Qingyi R. Jia

Chengdu, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

MANF attenuates cholestatic liver injury by enhancing GRP78-PERK interaction.

MANF attenuates cholestatic liver injury by enhancing GRP78-PERK interaction.

Journal: Biochemical pharmacology
Published: August 20, 2026

Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.

Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.

Journal: BMJ (Clinical research ed.)
Published: July 08, 2026

Annual monitoring and analysis of airborne pollen in Chengdu urban area of Sichuan Province

Annual monitoring and analysis of airborne pollen in Chengdu urban area of Sichuan Province

Journal: Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Published: March 19, 2026

STAT1 gain-of-function mutation leading to disseminated Talaromyces marneffei infection combined with hemophagocytic syndrome: a case report

STAT1 gain-of-function mutation leading to disseminated Talaromyces marneffei infection combined with hemophagocytic syndrome: a case report

Journal: Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
Published: February 02, 2026

Neuroplastin-55 is a receptor of Manf and protects against diet-induced obesity by promoting adipose browning.

Neuroplastin-55 is a receptor of Manf and protects against diet-induced obesity by promoting adipose browning.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: November 24, 2025

Obesity care in Chinese adults: from evidence to clinical practice.

Obesity care in Chinese adults: from evidence to clinical practice.

Journal: Precision clinical medicine
Published: October 23, 2025

A two-pronged nanomedicine counteracts obesity by remodeling adipose niche.

A two-pronged nanomedicine counteracts obesity by remodeling adipose niche.

Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: September 16, 2025

Proteomic variation underlies the heterogeneous risk of metabolic dysfunction-associated steatotic liver disease for subsequent chronic diseases.

Proteomic variation underlies the heterogeneous risk of metabolic dysfunction-associated steatotic liver disease for subsequent chronic diseases.

Journal: European journal of endocrinology
Published: January 27, 2025

Adipose tissue-targeting nanomedicines for obesity pharmacotherapy.

Adipose tissue-targeting nanomedicines for obesity pharmacotherapy.

Journal: Trends in endocrinology and metabolism: TEM
Published: October 16, 2024

Incidence, prevalence, and burden of type 2 diabetes in China: Trend and projection from 1990 to 2050.

Incidence, prevalence, and burden of type 2 diabetes in China: Trend and projection from 1990 to 2050.

Journal: Chinese medical journal
Published: August 11, 2024

Commentary: Shared decision making for weight-lowering medications in China.

Commentary: Shared decision making for weight-lowering medications in China.

Journal: Clinical and translational medicine
Published: July 10, 2024

Reactive Oxygen Species-Responsive Delivery of a Notch Inhibitor to Alleviate Nonalcoholic Steatohepatitis by Inhibiting Hepatic de Novo Lipogenesis and Inflammation.

Reactive Oxygen Species-Responsive Delivery of a Notch Inhibitor to Alleviate Nonalcoholic Steatohepatitis by Inhibiting Hepatic de Novo Lipogenesis and Inflammation.

Journal: Molecular pharmaceutics
Published: May 16, 2024
Showing 1-12 of 29

Last Updated: 09/26/2026